Follow Us
© 2026 Arizent. All rights reserved.
More than $6.4 billion in healthcare deals were announced on Monday at the annual JPMorgan Healthcare Conference in San Francisco as companies like Johnson & Johnson and Merck look to acquisitions to replenish their revenue streams.
The deals include Merck’s $680 million purchase of cancer drugmaker Harpoon Therapeutics, Boston Scientific’s $3.7 billion acquisition of device-maker Axonics and J&J’s $2 billion deal to buy Ambrx Biopharma, whose therapies target tumors with lethal drugs.
For reprint and licensing requests for this article, click here.
Much has been written recently about the increased scrutiny of employer's fiduciary responsibility related to the health and welfare plans offered to their employees.
A rivalry is heating up between the two drugmakers.
The founder of an ETF that tracks all American public companies with female CEOs sits down with American Banker Editor-in-Chief Chana Schoenberger to discuss why it matters if a company has a woman as CEO.
Ten drugs will be negotiated under Medicare in an element of President Biden's signature Inflation Reduction Act.
Promised bonuses and pay increases will still be paid after a tumultuous week that ended in the 166 year-old lender being taken over by its largest rival UBS Group.
